S'abonner

Natural products as chemo-radiation therapy sensitizers in cancers - 10/09/22

Doi : 10.1016/j.biopha.2022.113610 
Sabah Nisar a, Tariq Masoodi b, Kirti S. Prabhu c, 1, Shilpa Kuttikrishnan c, 1, Lubna Zarif c, 1, Summaiya Khatoon a, Shahid Ali d, Shahab Uddin c, e, Ammira Al-Shabeeb Akil a, Mayank Singh f, , 2 , Muzafar A. Macha g, , 2 , Ajaz A. Bhat a, , 2
a Depertment of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar 
b Laboratory of Cancer immunology and genetics, Sidra Medicine, Qatar 
c Translational Research Institute, Academic Health System, Hamad Medical Corporation, Qatar 
d International Potato Center (CIP), Shillong, Meghalaya, India 
e Laboratory Animal Research Center, Qatar University, Doha, Qatar 
f Department of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, AIIMS, New Delhi, India 
g Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Jammu & Kashmir, India 

Correspondence to: Department of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.Department of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS)New Delhi110029India⁎⁎Correspondence to: Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology (IUST), 192122, Jammu and Kashmir, India.Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology (IUST)Jammu and Kashmir192122India⁎⁎⁎Correspondence to: Department of Human Genetics, Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, PO BOX 26999 Doha, Qatar.Department of Human Genetics, Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra MedicinePO BOX 26999DohaQatar

Abstract

Cancer is a devastating disease and is the second leading cause of death worldwide. Surgery, chemotherapy (CT), and/or radiation therapy (RT) are the treatment of choice for most advanced tumors. Unfortunately, treatment failure due to intrinsic and acquired resistance to the current CT and RT is a significant challenge associated with poor patient prognosis. There is an urgent need to develop and identify agents that can sensitize tumor cells to chemo-radiation therapy (CRT) with minimal cytotoxicity to the healthy tissues. While many recent studies have identified the underlying molecular mechanisms and therapeutic targets for CRT failure, using small molecule inhibitors to chemo/radio sensitize tumors is associated with high toxicity and increased morbidity. Natural products have long been used as chemopreventive agents in many cancers. Combining many of these compounds with the standard chemotherapeutic agents or with RT has shown synergistic effects on cancer cell death and overall improvement in patient survival. Based on the available data, there is strong evidence that natural products have a robust therapeutic potential along with CRT and their well-known chemopreventive effects in many solid tumors. This review article reports updated literature on different natural products used as CT or RT sensitizers in many solid tumors. This is the first review discussing CT and RT sensitizers together in cancer.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




ga1

Le texte complet de cet article est disponible en PDF.

Highlights

Even though chemo and radiotherapy represent an essential component of cancer treatment, most cancer patients experience harmful side effects.
Several agents are utilized in clinical settings to boost the effectiveness of chemo and radiotherapy while reducing normal tissue toxicity.
Agents that enhance chemo or radiation-induced tumor cell killing or protect normal tissues from side effects are termed modifiers or sensitizers.
Natural‐based alternatives with less toxicity and their ability to sensitize tumor cells are in dire need.

Le texte complet de cet article est disponible en PDF.

Keywords : Natural product, Cancer, Chemotherapy, Radiotherapy, Cytotoxicity, Apoptosis, Immunosuppression, Anti-Inflammatory


Plan


© 2022  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 154

Article 113610- octobre 2022 Retour au numéro
Article précédent Article précédent
  • Role of curcumin in selected head and neck lesions. Limitations on the use of the Hep-2 cell line: A critical review
  • Ludwika Piwowarczyk, Maciej Stawny, Krzysztof Piwowarczyk, Dariusz T. Mlynarczyk, Izabela Muszalska-Kolos, Malgorzata Wierzbicka, Tomasz Goslinski, Anna Jelinska
| Article suivant Article suivant
  • The emerging role of noncoding RNAs in the Hedgehog signaling pathway in cancer
  • Xue Han, Bo Li

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.